glp-1 drug companies Analogues Market Size, Share & Growth Drivers By 2034 GLP-1 Market Industry Trends and
Description
H.MillerH
All GLP-1RAs [reviewed in (81)] and, more recently, the dual incretin receptor agonist tirzepatide, have been shown to lower postprandial triglyceride and ApoB-48 levels significantly (82)
Diabetes 32 (1), 1419
Mounjaro (tirzepatide) Approved - A dual-action injectable targeting GLP-1 and GIP receptors
(172) demonstrated that intravenous infusion of porcine GIP abolished plasma hypertriglyceridemia in rats during the fat load, while rats pretreated with GIP antiserum exhibited a significantly greater triglyceride increment late in the fat load time course
Baggio LL, et al
